Correlation Between Cognitive Function and Serum Irisin Levels in Parkinson's Disease Patients.
8 affiliations
- 1Department of Neurology, Second Xiangya Hospital, Central South University, Changsha, China.
- 2Clinical Medical Research Center for Stroke Prevention and Treatment of Hunan Province, Department of Neurology, Second Xiangya Hospital, Central South University, Changsha, China.
- 3Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China.
- 4Center For Medical Genetics, School of Life Sciences, Central South University, Changsha, China.
- 5National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China.
- 6Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
- 7Department of Medical Genetics, The Second Xiangya Hospital, Central South University, Changsha, China.
- 8Department of Medical Genetics, Hunan Province Clinical Medical Research Center For Genetic Birth Defects and Rare Diseases, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Abstract
Introduction
Cognitive impairment is a common non-motor symptom of Parkinson's disease (PD) that markedly reduces patients' quality of life. Given the clinical heterogeneity of PD-related cognitive impairment (PDCI), further clarification of clinical and circulating biological factors associated with cognitive status may help improve our understanding of cognitive dysfunction in PD.Methods
In this cross-sectional study, 243 patients with PD and 90 age- and sex-matched healthy controls (HCs) were enrolled. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA), and patients with PD were classified into the PD with cognitive impairment (PDCI) and PD without cognitive impairment (PDNCI) groups. Based on motor symptoms, PD patients were further divided into three subtypes: tremor-dominant (TD), postural instability and gait disorder (PIGD), and indeterminate subtype (IND). Group comparisons and logistic regression analyses were performed to examine factors associated with cognitive impairment.Results
Serum irisin levels did not differ significantly between patients with PD and healthy controls (p = 0.478). Compared with PDNCI patients, those with PDCI had lower serum irisin levels. Among motor subtypes, the PIGD group showed a higher prevalence of cognitive impairment (68.8% vs. 46.2%, p < 0.001) and significantly lower irisin levels compared with the TD group [3.25 (2.62-4.14) vs. 4.12 (3.42-5.07) µg/mL, p < 0.001]. Serum irisin levels were weakly but positively associated with memory performance, and this association remained significant after FDR correction across the five cognitive domains (r = 0.194, FDR-adjusted p = 0.010). Compared with patients in the TD-high irisin group, those in the PIGD-low irisin group had higher odds of concurrent cognitive impairment (OR = 6.065, 95% CI: 2.974-18.638, p = 0.002).Conclusion
Cognitive impairment was common among patients with PD, particularly those with the PIGD subtype. The PIGD subtype and lower serum irisin levels were associated with the presence of PDCI. In the joint-category analysis, patients in the PIGD-low-irisin group had higher odds of concurrent cognitive impairment than those in the TD-high-irisin group.
Related
- Correlation of peripheral blood BMAL1 level with non-motor symptoms in Parkinson’s disease patients
- Effects of dual-task training on health-related quality of life and cognitive function in people with Parkinson’s disease: a systematic review and meta-analysis
- Effects of exercise interventions on gait, motor function, and balance in patients with Parkinson’s disease: A meta-analysis with clinical implications
- Effects of mind–body exercise on motor function, quality of life, and depressive symptoms in patients with Parkinson’s disease: a systematic review and network meta-analysis
- Depression, anxiety, and cognitive function in patients with ischemic cerebrovascular disease: a cross-sectional study based on the Montreal Cognitive Assessment
BibTeX
@article{gui2026correlation,
title = {{Correlation Between Cognitive Function and Serum Irisin Levels in Parkinson's Disease Patients.}},
author = {Meilin Gui and Lixia Qin and Lingling Lv and Jinduo Huang and Shenglan Hu and Kexin Chen and Xing Wang and Yiwen Zhou and Beisha Tang and Hainan Zhang and Chunyu Wang},
journal = {Brain and behavior},
year = {2026},
month = oct,
doi = {10.1002/brb3.71848},
url = {https://europepmc.org/article/MED/42905889},
note = {CC BY},
}
RIS
TY - JOUR
TI - Correlation Between Cognitive Function and Serum Irisin Levels in Parkinson's Disease Patients.
AU - Meilin Gui
AU - Lixia Qin
AU - Lingling Lv
AU - Jinduo Huang
AU - Shenglan Hu
AU - Kexin Chen
AU - Xing Wang
AU - Yiwen Zhou
AU - Beisha Tang
AU - Hainan Zhang
AU - Chunyu Wang
PY - 2026
DA - 2026/10/01
JO - Brain and behavior
DO - 10.1002/brb3.71848
UR - https://europepmc.org/article/MED/42905889
AB - Introduction Cognitive impairment is a common non-motor symptom of Parkinson's disease (PD) that markedly reduces patients' quality of life. Given the clinical heterogeneity of PD-related cognitive impairment (PDCI), further clarification of clinical and circulating biological factors associated with cognitive status may help improve our understanding of cognitive dysfunction in PD.Methods In this cross-sectional study, 243 patients with PD and 90 age- and sex-matched healthy controls (HCs) were enrolled. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA), and patients with PD were classified into the PD with cognitive impairment (PDCI) and PD without cognitive impairment (PDNCI) groups. Based on motor symptoms, PD patients were further divided into three subtypes: tremor-dominant (TD), postural instability and gait disorder (PIGD), and indeterminate subtype (IND). Group comparisons and logistic regression analyses were performed to examine factors associated with cognitive impairment.Results Serum irisin levels did not differ significantly between patients with PD and healthy controls (p = 0.478). Compared with PDNCI patients, those with PDCI had lower serum irisin levels. Among motor subtypes, the PIGD group showed a higher prevalence of cognitive impairment (68.8% vs. 46.2%, p < 0.001) and significantly lower irisin levels compared with the TD group [3.25 (2.62-4.14) vs. 4.12 (3.42-5.07) µg/mL, p < 0.001]. Serum irisin levels were weakly but positively associated with memory performance, and this association remained significant after FDR correction across the five cognitive domains (r = 0.194, FDR-adjusted p = 0.010). Compared with patients in the TD-high irisin group, those in the PIGD-low irisin group had higher odds of concurrent cognitive impairment (OR = 6.065, 95% CI: 2.974-18.638, p = 0.002).Conclusion Cognitive impairment was common among patients with PD, particularly those with the PIGD subtype. The PIGD subtype and lower serum irisin levels were associated with the presence of PDCI. In the joint-category analysis, patients in the PIGD-low-irisin group had higher odds of concurrent cognitive impairment than those in the TD-high-irisin group.
SN - 2162-3279
ER -